The only two people lucky enough to be cured of HIV infection were unlucky enough to find themselves with cancer and HIV at the same time. What saved them both were stem cell transplants from bone marrow donors — last-ditch attempts to save them from the cancers. In the process, doctors used donors who had a genetic mutation rendering them, and their bone marrow cells, resistant to the virus.
The right reaction to the news of the second cure is, as several researchers have told me, nuanced. It is a big deal to AIDS researchers, who for years have been quietly seeking to go beyond managing the disease and shoot for a complete cure. This second case shows what might be possible with a lot more work.
However, there is an ever-present danger of raising false hopes for millions of people living with HIV, because a stem cell transplant is neither practical nor safe enough to use on anyone who has just HIV and not an otherwise fatal cancer.
Illustration: Constance Chou
AIDS researchers have raised false hope before. In 1997, David Ho (何大偉) of the Aaron Diamond Institute announced that the new crop of antiretroviral drugs would probably be able to knock out the virus in patients after they continued the regimen for a number of years.
He was soon proven wrong, when scientists discovered that the virus is very good at hiding from part of the immune system called memory T-cells.
So, cowed by that failure, the research community nearly ignored the news that an obscure doctor in Berlin cured a patient, Timothy Brown, using a stem cell transplant in 2008.
Journals refused to publish a paper, the New York Times played the story deep inside the newspaper, and at a major meeting, the researcher, Hero Hutter, was relegated to a mere poster session.
A few people recognized the importance of the case, including AIDS researcher Steven Deeks at the University of California, San Francisco, who later became the doctor treating Brown, who had become known as the Berlin patient.
Deeks told me that at the time the claim was believable because the biology all made sense. The Berlin patient had his immune cells replaced with ones from a donor with a genetic mutation that disables a receptor called CCR5.
Cells without a working CCR5 receptor are essentially locked up to the virus.
While bone marrow transplants are not likely to become standard HIV treatment, Deeks said there is promising research in using gene therapy to alter the CCR5 receptors.
Some are doing this using a so-called viral vector, to insert the HIV-resistant version of the gene into cells, and others are trying to remove a patient’s bone marrow, treat it and return it with at least some resistant cells.
These avenues, if they succeed, might not completely eradicate the virus from the body, but there is hope they might allow the patients to stay healthy without a daily drug regimen, which is both expensive, and for some, onerous.
One limitation of antiretroviral therapy is that patients who carry the virus for a few years without getting treatment can suffer damage to their immune systems. They can generate a constant, low-level immune response that increases the risk of heart disease and cancer, and can accelerate aging.
Since effective antiviral drugs did not exist before the mid-1990s, many people infected before this time suffer from these long-term effects.
Harvard AIDS researcher Bruce Walker said that if you talk to people who are taking HIV medications, they desperately want to get off them.
“They are tethered to these drugs that don’t make them feel sick but don’t make them feel normal either,” he said.
What they really want is a cure.
He is hoping that this second cure case will call attention to his work on another group of unusual people — not those with the mutation that makes them resistant to HIV, but another small fraction who test positive for HIV, yet never develop a detectable virus and never get sick.
Walker has tracked such people, dubbed elite controllers, and is starting to figure out how they become infected but remain functionally cured.
Walker said another positive sign with this second cure is that in the first case, the transplant almost killed the patient, but in this case, it did not.
However, between the first cure and the second there were a number of attempts to cure similar patients with stem cell transplants and all failed.
This was extremely discouraging, but researchers learned from all the failures, Deeks said.
Sometimes the transplant failed to take, or sometimes the cancer was too advanced. In a few other cases, the virus had mutated to a form called X4, which is still able to get into the modified cells.
Other people are hoping that even without a cure, new drugs that prevent infections can help stem the spread of HIV until, some years in the future, it is eradicated from the human race.
It is a good goal, but a cure would help millions of HIV patients. There are about 38,000 new cases reported each year in the US and 1.8 million worldwide, and the virus keeps surprising researchers, so it is best to keep up the fight on all fronts.
Faye Flam is a Bloomberg Opinion columnist. She has written for The Economist, the New York Times, the Washington Post, Psychology Today, Science and other publications. She has a degree in geophysics from the California Institute of Technology. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry